Advertisement

Correction to: Differentiating societal costs of disability worsening in multiple sclerosis

  • Nils-Henning Ness
  • Dirk Schriefer
  • Rocco Haase
  • Benjamin Ettle
  • Christian Cornelissen
  • Tjalf ZiemssenEmail author
Correction

Correction to: Journal of Neurology https://doi.org/10.1007/s00415-019-09676-4

The original version of this article unfortunately contained a mistake. The captions of Figs. 2 and 3 are mismatched.

The correct captions of Figs. 2 and 3 are given in the following page.

The original article has been corrected.
Fig. 2

Effects (IRR, 95% CI) of PIRA and RAW on the quarterly economic costs compared to DAF. PIRA increased the quarterly total costs by 29% over 2 years compared to DAF. Results were adjusted for age, gender, EDSS, time and data source. PIRA progression independent of relapse activity, RAW relapse-associated worsening, DAF disease activity free. *p < 0.05; **p < 0.01

Fig. 3

Comparison of patients with in- and outpatient hospitalizations within 2 years. In the RAW population, the rate of patients with at least one inpatient hospital stay was almost twice as high compared to PIRA population (18% vs. 32%)

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Authors and Affiliations

  1. 1.MS Center, Center of Clinical Neuroscience, Department of NeurologyUniversity Hospital Carl Gustav CarusDresdenGermany
  2. 2.Novartis Pharma GmbHNurembergGermany
  3. 3.Siemens Healthineers AGErlangenGermany

Personalised recommendations